
Scaled Biolabs speeds up discovery and development of cell-based medicines by systematically mapping cellular responses across large experimental sets. It operates a Cell Therapy Discovery Engine that combines microfluidics, laboratory automation, and machine learning to screen hundreds of parameters across tens of thousands of experiments. The platform is offered as a discovery and development service and platform for biotech and pharmaceutical customers (B2B), and the company also advances internal cell therapy programs. Core technologies include microfluidic assay platforms, automated robotics, and ML-driven analytics to optimize cell products and processes. Scaled Biolabs targets the growing cell therapy market, aiming to shorten development timelines and improve manufacturability and clinical outcomes.

Scaled Biolabs speeds up discovery and development of cell-based medicines by systematically mapping cellular responses across large experimental sets. It operates a Cell Therapy Discovery Engine that combines microfluidics, laboratory automation, and machine learning to screen hundreds of parameters across tens of thousands of experiments. The platform is offered as a discovery and development service and platform for biotech and pharmaceutical customers (B2B), and the company also advances internal cell therapy programs. Core technologies include microfluidic assay platforms, automated robotics, and ML-driven analytics to optimize cell products and processes. Scaled Biolabs targets the growing cell therapy market, aiming to shorten development timelines and improve manufacturability and clinical outcomes.
What they do: Lab-on-a-chip microfluidic platform that parallelizes and automates thousands of cell experiments to accelerate discovery and development of cell-, gene-, and biologic therapies.
Business model: B2B discovery and development service and platform for biotech and pharmaceutical customers; also advances internal cell therapy programs.
Core tech: Microfluidic assay platforms, laboratory automation/robotics, and machine-learning analytics.
Founded / HQ: 2016; San Francisco, California
Notable backers: SOSV / IndieBio and California Institute for Regenerative Medicine (CIRM)
Cell therapy, gene therapy, and biologics discovery and development; optimizing cell products and processes to improve manufacturability and clinical outcomes.
2016
Biotechnology
“Backed by accelerators/venture groups SOSV and IndieBio and received grant support from the California Institute for Regenerative Medicine”